AI-generated analysis. Always verify with the original filing.
Lixte Biotechnology Holdings, Inc. filed an 8-K on March 10, 2026, disclosing under Item 1.01 entry into a material definitive agreement on March 6, 2026, with Liora Technologies Europe Ltd, a subsidiary, involving an Amended and Restated Share Exchange Agreement as Exhibit 10.1.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 6, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), Liora Technologies Europe Ltd, a subsidiary o
Financial Statements and Exhibits (d) Exhibits. The following exhibits are filed herewith. Exhibit Number Description 10.1 Amended and Restated Share Exchange A
Material Agreement